Oct. 23 at 6:18 PM
$HRTX Here’s the biggest reason Heron Therapeutics, Inc. (“Heron”) is positioned to be a top biotech in the non-opioid pain space — and yes, they also play into cancer/oncology angles:
🎯 Their core differentiator: non-opioid pain relief
Their flagship product ZYNRELEF® is described as the first and only extended-release dual-acting local anesthetic combining a local anesthetic (bupivacaine) + NSAID (meloxicam), for up to 72 hours of postsurgical analgesia.
In clinical settings, ZYNRELEF resulted in significantly more patients requiring no opioids through the first 72 hours post surgery, compared to standard bupivacaine solution.
It was also added as a qualifying product under the proposed 2025 non-opioid pain relief policy by Centers for Medicare & Medicaid Services (CMS) for hospital and outpatient surgical settings — that means strong reimbursement tailwinds.
